Nycomed continues to outperform in emerging markets in first quarter 2011
- Details
- Category: Nycomed
Nycomed announced results for the first quarter of 2011, demonstrating continued outperformance in the key emerging economies which are driving growth in the global pharmaceuticals industry.
GSK forms partnership with three leading NGOs
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced further progress on its commitment to reinvest 20% of profits made in the Least Developed Countries (LDCs) back into projects that strengthen the healthcare infrastructure in those countries.
AstraZeneca signs agreement in Japan with Daiichi Sankyo to co-promote denosumab
- Details
- Category: AstraZeneca
AstraZeneca announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis.
Lilly and Investor Group Form New Critical Care Company BioCritica
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company.
Sanofi's Commitment to Research and Identify Treatments for Cancer Patients
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced that data from eight compounds in the company's robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.
SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
- Details
- Category: Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease.
Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis.
More Pharma News ...
- Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO
- Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc.
- Pfizer To Present New Research From Fifteen Compounds
- Patrick Dempsey Teams up With Breakaway from Cancer(R)
- New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer
- Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research
- Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study